Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Myeloperoxidase Deficiency Medication

  • Author: Maureen M Petersen, MD; Chief Editor: Harumi Jyonouchi, MD  more...
 
Updated: Nov 17, 2014
 
 

Medication Summary

See Medical Care.

 
 
Contributor Information and Disclosures
Author

Maureen M Petersen, MD Staff Physician in Allergy and Immunology, Walter Reed National Military Medical Center; National Capital Consortium Transitional Year Program Director; Assistant Professor of Pediatrics and Assistant Professor of Medicine, Uniformed Services University of the Health Sciences

Maureen M Petersen, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma and Immunology, American Thoracic Society, Clinical Immunology Society

Disclosure: Nothing to disclose.

Coauthor(s)

Cecilia P Mikita, MD, MPH Associate Program Director, Allergy-Immunology Fellowship, Associate Professor of Pediatrics and Medicine, Uniformed Services University of the Health Sciences; Staff Allergist/Immunologist, Walter Reed National Military Medical Center

Cecilia P Mikita, MD, MPH is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David J Valacer, MD 

David J Valacer, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American Thoracic Society, New York Academy of Sciences

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD Faculty, Division of Allergy/Immunology and Infectious Diseases, Department of Pediatrics, Saint Peter's University Hospital

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Pediatric Research, Society for Mucosal Immunology

Disclosure: Nothing to disclose.

Additional Contributors

C Lucy Park, MD Chief, Division of Allergy, Immunology, and Pulmonology, Associate Professor, Department of Pediatrics, University of Illinois at Chicago College of Medicine

C Lucy Park, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, Chicago Medical Society, American Medical Association, Clinical Immunology Society, Illinois State Medical Society

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Javed Sheikh, MD to the development and writing of this article.

References
  1. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood. Aug 2008. 112:935-945. [Medline].

  2. Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol. 2012 Oct 11. [Medline].

  3. Stefanescu A, Braun S, Ndrepepa G, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J. Feb 2008. 155:356-360. [Medline].

  4. Kutter D, Devaquet P, Vanderstocken G, et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol. 2000. 104(1):10-5. [Medline].

  5. Rudolph TK, Wipper S, Reiter B, Rudolph V, Coym A, Detter C, et al. Myeloperoxidase deficiency preserves vasomotor function in humans. Eur Heart J. 2012 Jul. 33(13):1625-34. [Medline]. [Full Text].

  6. Nauseef WM. Insights into myeloperoxidase biosynthesis from its inherited deficiency. J Mol Med. 1998 Sep. 76(10):661-8. [Medline].

  7. Nauseef WM. Lessons from MPO deficiency about functionally important structural features. Jpn J Infect Dis. 2004 Oct. 57(5):S4-5. [Medline].

  8. Lanza F. Clinical manifestation of myeloperoxidase deficiency. J Mol Med. 1998 Sep. 76(10):676-81. [Medline].

  9. Kutter D. Prevalence of myeloperoxidase deficiency: population studies using Bayer-Technicon automated hematology. J Mol Med. 1998 Sep. 76(10):669-75. [Medline].

  10. Nunoi H, Kohi F, Kajiwara H, Suzuki K. Prevalence of inherited myeloperoxidase deficiency in Japan. Microbiol Immunol. 2003. 47(7):527-31. [Medline].

  11. Taioli E, Benhamou S, Bouchardy C, et al. Myeloperoxidase G463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. Feb 2007. 9:67-73. [Medline].

  12. Nauseef WM, Cogley M, and McCormick S. Effect of the R569W missense mutation on the bio-synthesis of myeloperoxidase. J Biol Chem. Apr 1996. 271:9546-9549. [Medline].

  13. Ohashi YY, Kameoka Y, Persad AS, et al. Novel missense mutation found in a Japanese patient with myeloperoxidase deficiency. Gene. 2004 Mar 3. 327(2):195-200. [Medline].

  14. Persad AS, Kameoka Y, Kanda S, Niho Y, Suzuki K. Arginine to cysteine mutation (R499C) found in a Japanese patient with complete myeloperoxidase deficiency. Gene Expr. 2006. 13(2):67-71. [Medline].

  15. Nauseef WM. Diagnostic assays for myeloperoxidase and myeloperoxidase deficiency. Methods Mol Biol. 2014. 1124:537-46. [Medline].

  16. Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev. 2007 Oct. 219:88-102. [Medline].

  17. Mauch L, Lun A, O'Gorman MRG, et al. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem. Mar 2007. 53:890-896. [Medline].

  18. Boxer LA, Blackwood RA. Leukocyte disorders: quantitative and qualitative disorders of the neutrophil, part 2. Pediatr Rev. 1996 Feb. 17(2):47-50. [Medline].

  19. DeLeo FR, Goedken M, McCormick SJ, Nauseef WM. A novel form of hereditary myeloperoxidase deficiency linked to endoplasmic reticulum/proteasome degradation. J Clin Invest. 1998 Jun 15. 101(12):2900-9. [Medline]. [Full Text].

  20. Marchetti C, Patriarca P, Solero GP, Baralle FE, Romano M. Genetic characterization of myeloperoxidase deficiency in Italy. Hum Mutat. 2004 May. 23(5):496-505. [Medline].

  21. Marchetti C, Patriarca P, Solero GP, Baralle FE, Romano M. Genetic studies on myeloperoxidase deficiency in Italy. Jpn J Infect Dis. 2004 Oct. 57(5):S10-2. [Medline].

  22. Milla C, Yang S, Cornfield DN, et al. Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol. 2004 Oct. 287(4):L706-14. [Medline]. [Full Text].

  23. Molin L, Stendahl O. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand. 1979. 206(6):451-7. [Medline].

  24. Nauseef WM. Myeloperoxidase deficiency. Hematol Pathol. 1990. 4(4):165-78. [Medline].

  25. Nauseef WM. Myeloperoxidase deficiency. Hematol Oncol Clin North Am. 1988 Mar. 2(1):135-58. [Medline].

  26. Nauseef WM. Quality control in the endoplasmic reticulum: lessons from hereditary myeloperoxidase deficiency. J Lab Clin Med. 1999 Sep. 134(3):215-21. [Medline].

  27. Nauseef WM, Cogley M, Bock S, Petrides PE. Pattern of inheritance in hereditary myeloperoxidase deficiency associated with the R569W missense mutation. J Leukoc Biol. 1998 Feb. 63(2):264-9. [Medline].

  28. Petrides PE. Molecular genetics of peroxidase deficiency. J Mol Med. 1998 Sep. 76(10):688-98. [Medline].

  29. Petrides PE, Nauseef WM. Molecular and clinical aspects of neutrophil peroxidase deficiency: multidisciplinary approaches on an international scale. J Mol Med. 1998 Sep. 76(10):659-60. [Medline].

  30. Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest. 1978 Jul. 62(1):214-20. [Medline]. [Full Text].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.